TY - JOUR
T1 - Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome
AU - Grugni, G.
AU - Marzullo, P.
AU - Ragusa, L.
AU - Sartorio, A.
AU - Trifirò, G.
AU - Liuzzi, A.
AU - Crinò, A.
PY - 2006/10
Y1 - 2006/10
N2 - Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P < 0·02; AUC 956 ± 182·9 μg/l/h, P < 0·005). When considered individually, 17 of 44 PWS individuals (38·6%) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.
AB - Objective: It is unclear if poor health outcomes of adult patients with Prader-Willi syndrome (PWS) are influenced by GH deficiency (GHD). Few studies have been focused on PWS adults, but further information on the concomitant role of obesity on GH/IGF-I axis function is needed. The aim of our study was to investigate the prevalence of GHD in a large group of adult subjects with genetically confirmed PWS. Design and subjects: We studied the GH response to a combined administration of GHRH (1 μg/kg i.v. at 0 minutes) and arginine (ARG) (30 g i.v., infused from 0 to 30 minutes) as well as the baseline IGF-I levels, in a group of 44 PWS adults (18 males, 26 females) aged 18-41·1 years. The same protocol was carried out in a control group of 17 obese subjects (7 males, 10 females) aged 21·8-45·8 years. Measurements: Blood samples were taken at -15 and 0 minutes and then 30, 45, 60, 90 and 120 minutes after GHRH administration. Serum GH and total IGF-I concentrations were measured by chemioluminescence. Statistical analysis was performed by Student's t-test for unpaired data, and using analysis of variance for parametric and nonparametric (Mann-Whitney test) data, where appropriate. The relationship between pairs of variables was assessed by Pearson's correlation. Independent variables influencing GH secretion were tested by multiple linear regression analysis. Results: The GH response to GHRH + ARG was significantly lower in PWS patients (GH peak (mean ± SE) 8·4 ± 1·2 μg/l; AUC: 471·4 ± 77·8 μg/l/h) than obese subjects (GH peak 15·7 ± 2·9 μg/l, P < 0·02; AUC 956 ± 182·9 μg/l/h, P < 0·005). When considered individually, 17 of 44 PWS individuals (38·6%) were severely GHD, according to the cut-off limit of 4·1 μg/l for obese individuals, and low IGF-I-values were present in 33 PWS patients. Moreover, impaired GH response was combined with subnormal IGF-I levels in all PWS patients with GHD. Conclusions: Adult subjects with PWS had a reduced responsiveness to GHRH + ARG administration associated with reduced IGF-I levels. In addition, a severe GHD for age was demonstrated in a significant percentage of PWS subjects. These findings are in agreement with the hypothesis that a complex derangement of hypothalamus-pituitary axis occurred in PWS, and suggested that impaired GH secretion is not an artefact of obesity.
UR - http://www.scopus.com/inward/record.url?scp=33748805758&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2006.02621.x
DO - 10.1111/j.1365-2265.2006.02621.x
M3 - Article
SN - 0300-0664
VL - 65
SP - 492
EP - 499
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 4
ER -